Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan

Hsi Che Liu, Shu Huey Chen, Kou Hwa Chang, Le Chiao Chiang, Chin Yueh Liu, Huei Lan Chang, Li Li Tsai, Der Cherng Liang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalPediatric Hematology and Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Neurology
Taiwan
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Central Nervous System
Therapeutics
Remission Induction
Vincristine
Pharmaceutical Preparations
Dexamethasone
Maintenance
Therapy
Clinical Trials
Recurrence
Survival
Childhood
Drugs
Population

Keywords

  • Acute lymphoblastic leukemia
  • Epirubicin
  • Long-term treatment results

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan. / Liu, Hsi Che; Chen, Shu Huey; Chang, Kou Hwa; Chiang, Le Chiao; Liu, Chin Yueh; Chang, Huei Lan; Tsai, Li Li; Liang, Der Cherng.

In: Pediatric Hematology and Oncology, Vol. 19, No. 1, 2002, p. 19-29.

Research output: Contribution to journalArticle

Liu, Hsi Che ; Chen, Shu Huey ; Chang, Kou Hwa ; Chiang, Le Chiao ; Liu, Chin Yueh ; Chang, Huei Lan ; Tsai, Li Li ; Liang, Der Cherng. / Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan. In: Pediatric Hematology and Oncology. 2002 ; Vol. 19, No. 1. pp. 19-29.
@article{63c016e4293742969b24879bc3cb3202,
title = "Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan",
abstract = "The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1{\%} and 64 ± 4.3{\%}, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3{\%}. The dropout rate significantaly decreased from 35{\%} in 1982-1984 to 0{\%} in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.",
keywords = "Acute lymphoblastic leukemia, Epirubicin, Long-term treatment results",
author = "Liu, {Hsi Che} and Chen, {Shu Huey} and Chang, {Kou Hwa} and Chiang, {Le Chiao} and Liu, {Chin Yueh} and Chang, {Huei Lan} and Tsai, {Li Li} and Liang, {Der Cherng}",
year = "2002",
doi = "10.1080/088800102753356158",
language = "English",
volume = "19",
pages = "19--29",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan

AU - Liu, Hsi Che

AU - Chen, Shu Huey

AU - Chang, Kou Hwa

AU - Chiang, Le Chiao

AU - Liu, Chin Yueh

AU - Chang, Huei Lan

AU - Tsai, Li Li

AU - Liang, Der Cherng

PY - 2002

Y1 - 2002

N2 - The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.

AB - The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.

KW - Acute lymphoblastic leukemia

KW - Epirubicin

KW - Long-term treatment results

UR - http://www.scopus.com/inward/record.url?scp=0036088860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036088860&partnerID=8YFLogxK

U2 - 10.1080/088800102753356158

DO - 10.1080/088800102753356158

M3 - Article

VL - 19

SP - 19

EP - 29

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 1

ER -